In this episode, Dr. Hamrick opens up about how precision oncology is becoming a global, collaborative force in the fight against cancer. He shares how the Precision Oncology Alliance (POA) brings together the best minds in oncology to empower investigators with Caris’ robust molecular data and infrastructure — enabling them to answer key questions that directly improve cancer care and research.
We also explore:
Why comprehensive molecular testing is foundational for patients to truly understand what they’re facing — and how it guides clinicians toward more informed, personalized treatment decisions
How the 37 scientific abstracts presented at ASCO underscore the Alliance’s impact in advancing evidence-based precision medicine
How the POA fosters a collaborative, global community that encourages the cross-pollination of ideas across leading cancer centers
The emerging trend of mechanism-based and pathway-driven targeted therapies — and the rise of combination approaches grounded in molecular science
How AI is helping researchers and clinicians extract insight from vast DNA and RNA sequencing data, revealing patterns and trends that would otherwise go unseen
Dr. Hamrick’s insights are a compelling reminder that precision oncology isn’t just about innovation — it’s about giving patients answers, options, and hope through better diagnostics, deeper collaboration, and smarter use of data.
☕ Grab your favorite cup of tea and join us for this episode of #HITeaWithGrace, where science meets soul in the pursuit of better cancer care.
👉 Don’t forget to like, comment, and subscribe for more real talk on the future of oncology, innovation, and health tech.
#ASCO2025 #HITeaWithGrace #PrecisionOncology #ComprehensiveTesting #CancerCare #AIinOncology #MolecularSignatures #TargetedTherapies #CarisLifeSciences #ClinicalResearch #HealthIT #OncologyLeadership #PatientEmpowerment